Company / Working Capital
BridgeBio Pharma, Inc. Working Capital History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$509.8M
FY2025
5-year range
$333.7M / $753.8M
FY2021-FY2025
Trend
-10.0%
vs FY2024
Sector context
#91 of 213
Health Care
What the data says
At $510M, BridgeBio Pharma, Inc.'s working capital ranks #91 of 213 in the Health Care sector. Working Capital has fluctuated over the past 8 years, ranging from $334M in FY2023 to $754M in FY2021.
Based on SEC 10-K filings.
$510M in FY2025 with a 5-year CAGR of -1.4%.
Improved from $334M to $510M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +6.0%
- 5-Year CAGR
- -1.4%
- 10-Year CAGR
- -
Sector benchmark
#91 of 213 in Health CareTop 43% of 213This company $509.8M Sector average $934.6M
▼
-45.5% below sector average
Key checks
Key Insights
- 5-year CAGR of -1.4%, indicating a declining trend.
- In FY2025, working capital decreased 10.0% year-over-year.
- Ranks #91 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $509.8M | -10.0% |
| FY2024 | $566.3M | +69.7% |
| FY2023 | $333.7M | -21.9% |
| FY2022 | $427.4M | -43.3% |
| FY2021 | $753.8M | +37.8% |
| FY2020 | $547.2M | +7.7% |
| FY2019 | $508.2M | +23.2% |
| FY2018 | $412.6M | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026